Skip to content

Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders

Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07651917
Acronym
SPIRIT_1
Enrollment
50
Registered
2026-06-16
Start date
2026-06-18
Completion date
2026-07-31
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognition

Keywords

Hypoxia, Altitude, Supplemental oxygen therapy

Brief summary

Exposure to high altitudes, defined as locations above 2500 m, has been shown to cause cognitive alternations due to reduced blood oxygenation (SpO2). However, it remains to be determined whether cognitive changes are present in highlanders living at moderate altitudes (2500 m) and whether cognitive alterations are reversible with supplemental oxygen therapy (SOT).

Interventions

5 L/min supplemental oxygen therapy administered through nasal canula.

OTHERSham intervention

5 L/min sham intervention administered through nasal canula.

Sponsors

University of Zurich
Lead SponsorOTHER
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
CollaboratorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Signed written consent * Age \>18 * Kyrgyz ethnicity * Born, raised and living at approximately 2500 m * Native or fluent in Russian language

Exclusion criteria

* Severe disease such as unstable hypertension, coronary heart disease, pulmonary diseases, others. * Regular use of medication that interfere with sleep or breathing such as benzodiazepines, opioids, acetazolamide * Heavy smoking of \>20 cigarettes per day * Not able to read or adhere to the study protocol

Design outcomes

Primary

MeasureTime frameDescription
Psychomotor vigilance reaction timeComparison between SOT and sham after 15 minutes interventionThe difference in the reaction time during a 10-minute psychomotor vigilance test between SOT and Sham intervention.

Secondary

MeasureTime frameDescription
Trail making test performanceComparison between SOT and sham after 15 minutes interventionThe difference in the trial making test A performance between SOT and Sham intervention.
Stroop test performanceComparison between SOT and sham after 15 minutes interventionThe difference in the stroop test performance between SOT and Sham intervention.
Digit Span test performanceComparison between SOT and sham after 15 minutes interventionThe difference in the digit span test performance between SOT and Sham intervention.
Go / No-Go test performanceComparison between SOT and sham after 15 minutes interventionThe difference in the Go / No-Go test performance between SOT and Sham intervention.
N-back test performanceComparison between SOT and sham after 15 minutes interventionThe difference in the n-back test performance between SOT and Sham intervention.
Task Switching Cued test performanceComparison between SOT and sham after 15 minutes interventionThe difference in the task switching cued test performance between SOT and Sham intervention.
Flanker test performanceComparison between SOT and sham after 15 minutes interventionThe difference in the Flanker test performance between SOT and Sham intervention.
Corsi Span test performanceComparison between SOT and sham after 15 minutes interventionThe difference in the Corsi span test performance between SOT and Sham intervention.

Contacts

CONTACTMichael Furian, Prof. Dr.
michael.furian@usz.ch+41794037586
CONTACTEdith M Schneider, Dr.
edith.schneidergasser@usz.ch
PRINCIPAL_INVESTIGATORMichael Furian

University of Zurich

PRINCIPAL_INVESTIGATOREdith M Schneider, Dr.

University of Zurich

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026